Every 424B that Clearmind Medicine Inc. (CMND) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CMND and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMND filings page.
Clearmind Medicine Inc. is offering 7,944,868 common shares at $0.12 per share and pre-funded warrants to purchase up to 2,865,960 common shares at $0.1199 per warrant, for total gross proceeds of approximately $1,297,012.76. Each pre-funded warrant is immediately exercisable for one share at an exercise price of $0.0001 and has no expiration.
The company expects net proceeds of about $1.3 million, to be used for general corporate purposes including operating expenses, research and development, clinical and pre-clinical testing, working capital, potential acquisitions and capital expenditures. Shares outstanding were 33,181,024 as of November 25, 2025, and are expected to be 43,991,852 assuming full exercise of the pre-funded warrants. Clearmind has received a Nasdaq notice for not meeting the $2.5 million minimum stockholders’ equity requirement and plans to use this and recent financings to help regain compliance, while its auditors have highlighted substantial doubt about its ability to continue as a going concern.
Clearmind Medicine Inc. is conducting a primary offering of 10,925,000 common shares at $0.20 per share, for gross proceeds of $2,185,000 and estimated net proceeds of about $2.1 million. Shares outstanding will increase from 22,181,024 to 33,106,024, so this raise represents roughly half of the pre-offering share count. The company plans to use the cash for general corporate purposes, including operating expenses, clinical and pre-clinical development of its psychedelic-based treatments, working capital and possible acquisitions.
Clearmind is a clinical-stage pharmaceutical company developing MEAI-based therapies targeting alcohol use disorder, binge drinking, obesity and metabolic disorders, with an ongoing multinational Phase I/IIa trial. The company recently reported stockholders’ equity of $1,065,668, below Nasdaq’s $2.5 million minimum, and received a non-compliance notice. Management expects this offering, recent registered direct offerings, warrant exercises and prior note conversions to help address equity requirements, but notes that there is still a risk of Nasdaq delisting and its auditors have raised substantial doubt about the company’s ability to continue as a going concern.
Clearmind Medicine Inc. is offering 3,991,768 common shares and pre-funded warrants for up to 1,518,000 additional shares at $0.25 per share and $0.2499 per warrant, for gross proceeds of approximately $1.38 million before expenses. The company estimates net proceeds of about $1.3 million. Common shares outstanding were 16,671,256 as of November 14, 2025 and are expected to reach 22,181,024 if all pre-funded warrants are exercised. The cash will support general corporate purposes, including operating expenses, R&D and clinical trials.
Clearmind is a clinical-stage psychedelic medicine company developing MEAI-based treatments for alcohol use disorder, obesity, metabolic disorders and other addictive behaviors, with an ongoing multinational Phase I/IIa trial of CMND‑100 at sites including Yale and Johns Hopkins. The company recently received a Nasdaq notice for not meeting the $2.5 million minimum stockholders’ equity requirement, and its latest audited financials include substantial doubt about its ability to continue as a going concern. Management expects this offering, prior financings, warrant exercises and note conversions to help improve equity and support continued development.
Clearmind Medicine Inc. (CMND) launched a primary offering of 958,222 common shares at $0.20 per share and pre-funded warrants to purchase up to 2,984,143 common shares at $0.1999, together with the common shares issuable upon exercise of those warrants. Each pre-funded warrant is immediately exercisable for one share at $0.0001 and remains outstanding until fully exercised, subject to 4.99% (or 9.99% at holder election) beneficial ownership limits.
The company expects gross proceeds of $788,175 before expenses and estimates net proceeds of approximately $0.78 million, to be used for general corporate purposes, including R&D and working capital. Shares outstanding were 9,601,441 as of November 12, 2025; the company states 13,543,806 would be outstanding assuming full exercise of pre-funded warrants.
CMND disclosed a Nasdaq notice of non-compliance with the $2.5 million stockholders’ equity requirement after reporting $1,065,668 of equity and has until December 18, 2025 to submit a compliance plan. Delivery of securities is expected on or about November 14, 2025, subject to customary closing conditions.